Aducanumab for the treatment of Alzheimer's disease : a systematic review
© 2023 The Authors. Psychogeriatrics published by John Wiley & Sons Australia, Ltd on behalf of Japanese Psychogeriatric Society..
Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P < 0.05) and a slowed decline in cognition (22% reduction) in the high-dose treated group, difference of -0.39 versus placebo in Clinical Dementia Rating Scale Sum Boxes (95% CI, -0.69 to -0.09; P = 0.012) along with a reduced amyloid positron emission tomography standard uptake value ratio score (P < 0.001) and plasma p181-tau (phosphorylated tau) level. Amyloid-related imaging abnormality was reported as a serious adverse event and was profound in high-dose treated group (425/1029 in 10 mg/kg). Aducanumab has been reported to affect two main pathophysiologic hallmarks (Aβ and tau) of AD. We suggest future studies addressing aducanumab's efficacy and safety to confirm that the benefit of this drug outweighs the risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society - 23(2023), 3 vom: 29. Mai, Seite 512-522 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rahman, Afroza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
105J35OE21 |
|---|
| Anmerkungen: |
Date Completed 03.05.2023 Date Revised 03.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/psyg.12944 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352848758 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352848758 | ||
| 003 | DE-627 | ||
| 005 | 20231226054649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/psyg.12944 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352848758 | ||
| 035 | |a (NLM)36775284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rahman, Afroza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aducanumab for the treatment of Alzheimer's disease |b a systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2023 | ||
| 500 | |a Date Revised 03.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Psychogeriatrics published by John Wiley & Sons Australia, Ltd on behalf of Japanese Psychogeriatric Society. | ||
| 520 | |a Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P < 0.05) and a slowed decline in cognition (22% reduction) in the high-dose treated group, difference of -0.39 versus placebo in Clinical Dementia Rating Scale Sum Boxes (95% CI, -0.69 to -0.09; P = 0.012) along with a reduced amyloid positron emission tomography standard uptake value ratio score (P < 0.001) and plasma p181-tau (phosphorylated tau) level. Amyloid-related imaging abnormality was reported as a serious adverse event and was profound in high-dose treated group (425/1029 in 10 mg/kg). Aducanumab has been reported to affect two main pathophysiologic hallmarks (Aβ and tau) of AD. We suggest future studies addressing aducanumab's efficacy and safety to confirm that the benefit of this drug outweighs the risk | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alzheimer disease | |
| 650 | 4 | |a aducanumab | |
| 650 | 4 | |a aged | |
| 650 | 4 | |a drug safety profile | |
| 650 | 4 | |a efficacy | |
| 650 | 7 | |a aducanumab |2 NLM | |
| 650 | 7 | |a 105J35OE21 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 700 | 1 | |a Hossen, Md Anwar |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Mirza Farhana Iqbal |e verfasserin |4 aut | |
| 700 | 1 | |a Bari, Sadia |e verfasserin |4 aut | |
| 700 | 1 | |a Tamanna, Nuzhat |e verfasserin |4 aut | |
| 700 | 1 | |a Sultana, Syeda Salima |e verfasserin |4 aut | |
| 700 | 1 | |a Haque, Sharar Naiarin |e verfasserin |4 aut | |
| 700 | 1 | |a Al Masud, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Saif-Ur-Rahman, K M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society |d 2009 |g 23(2023), 3 vom: 29. Mai, Seite 512-522 |w (DE-627)NLM190014946 |x 1479-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:3 |g day:29 |g month:05 |g pages:512-522 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/psyg.12944 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 3 |b 29 |c 05 |h 512-522 | ||